From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

ELISA Development for Radiation Countermeasures

by Global Biodefense Staff
April 15, 2014

The Uniformed Services University of the Health Sciences (USUHS) is soliciting for a vendor to develop an ELISA (enzyme-linked immunosorbent assay) in support of ongoing radiation countermeasure research.

The awardee will to develop an improved ELISA to detect the peptide, ALXN41000TPO in non-human primates, and optimize sensitivity of the assay for the drug ALXN4100TPO.

ALXN41000TPO was developed by Alexion Pharmaceuticals. The drug company no longer makes this product. USUHS has a very limited supply of this compound and will only provide it to the awardee.

The current ELISA in use for this project employs sheep anti-human kappa light chain and sheep anti-human IgG. When monkey serum containing ALXN4100TPO is added to the ELISA plate coated with sheep anti-human IgG, together with ALXN4100TPO, monkey IgG will also bind to the sheep IgG. This results in excessive non-specific binding of the second antibody to this complex and a spuriously high signal.

The Government will provide the awardee with Government Furnished Material to include:
• ALX4100TP0 (approx 200 mg)
• Untreated pooled nonhuman serum samples (approx 4-5 ml)
• Antibody scaffold (approx 500 mg)

USUHS is the Nation’s federal health sciences university and is committed to excellence in military medicine and public health during peace and war. USUHS is located in Bethesda, MD on the campus of Naval Support Activity Bethesda.

Further details are available under Solicitation Number: HU0001-14-Q-0380.

From Our Partners
Tags: Radiation

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC